Summary of Key Points from Conference Call Records Industry Overview - **Precious Metals and Non-Ferrous Metals**: Significant price movements observed in precious metals, particularly gold, which surged over 2% to exceed $5100 per ounce, indicating strong market demand and investor interest [1][2]. Core Insights and Arguments - **Gold Market Performance**: The spot price of gold increased by 2.29%, marking a daily rise of over $110, reflecting robust investor sentiment and market dynamics [1]. - **Tungsten Market Trends**: - The price of black tungsten concentrate rose by 11.43% to 536,000 CNY per ton, while ammonium paratungstate increased by 12.06% to 790,000 CNY per ton, indicating tightening supply conditions [2][4]. - Supply constraints are evident as mining production slows down due to reduced extraction quotas, leading to a tightening of market circulation [3]. - **Tin Market Dynamics**: - SHFE tin prices rose by 21.85% to 429,600 CNY per ton, and LME tin prices increased by 21.73% to $54,200 per ton, driven by supply pressures from geopolitical issues in major production areas [4][5]. Additional Important Content - **Biopharmaceutical Sector**: The outbreak of the Nipah virus in West Bengal, India, has raised concerns, with multiple healthcare workers infected, prompting urgent preventive measures in neighboring countries [6]. - **Space Photovoltaics**: - Elon Musk announced plans for SpaceX and Tesla to establish 100 GW of solar capacity in the U.S. within three years, which could significantly boost long-term demand for space photovoltaics [6]. - The commercial space sector is entering a new phase of large-scale deployment, with over 200,000 satellite constellation applications submitted in China [6]. - **Cloud Computing and AI**: AWS has raised its EC2 machine learning capacity block prices by approximately 15%, indicating rising operational costs in the cloud computing sector [7]. - **Oil and Gas Market**: Natural gas prices in the U.S. surged due to winter storms, with futures exceeding $6 per million British thermal units for the first time since 2022, reflecting supply-demand imbalances [7]. Stock Performance Highlights - **Top Gainers**: - In the precious metals sector, stocks such as Hunan Gold, Sichuan Gold, and China Gold saw significant price increases [2]. - In the tungsten sector, stocks like Xianglu Tungsten and Zhongtung High-tech performed well [4]. - In the biopharmaceutical sector, companies like Maike Biotech and Kaili Biotech experienced notable stock gains [6]. - **Market Activity**: The total trading volume in the Shanghai and Shenzhen markets approached 3.3 trillion CNY, reflecting increased market activity compared to the previous trading day [1].

Group 1 - The core focus of the Minhang District's 2026 Action Plan is to enhance the business environment through four key areas: government services, industrial ecology, market competition, and social governance, with 19 specific tasks outlined [1] - The new 9.0 plan emphasizes creating a friendly and adaptable industrial environment, supporting the development of leading industries and enhancing core functions, while maintaining efficient government services and a transparent institutional framework [1] - The reform aims to combine five strategies and promote five transformations, positioning the optimization of the business environment as a crucial strategy for economic and social development, thereby supporting a strong start for the region's 14th Five-Year Plan [1] Group 2 - The 9.0 plan focuses on key industrial clusters such as new energy equipment, green low-carbon technologies, aerospace, and biomedicine, establishing a systematic service model tailored to each industry [2] - The district will enhance the "Zero Bay" technology innovation source area and the Yangtze River Delta manufacturing R&D cluster, optimizing the full-chain service for technological innovation and fostering new productive forces [2] - The plan prioritizes addressing enterprise issues and measuring success by enterprise satisfaction, introducing specific solutions to common problems, such as synchronizing power line planning with municipal road construction to reduce electricity access delays [2] Group 3 - The 9.0 plan incorporates digitalization and intelligent technologies to optimize service tools and re-engineer business processes and service ecosystems, enhancing overall governance efficiency [3] - The plan introduces a systematic approach to create a district-level government intelligence empowerment system, launching new paradigms for "smart government" applications [3] - Minhang District leadership emphasizes that improving the business environment is essential for building an innovative, open, and livable modern urban area, committing to proactive implementation of the plan for significant advancements in the business environment [3]

Group 1 - The core viewpoint of the news is that Nocera Biopharma experienced a decline in stock price and significant trading activity, indicating high investor interest and potential volatility in the stock [1] - On January 26, Nocera Biopharma's stock fell by 2.02%, with a trading volume of 186 million yuan. The net financing purchase was 2.6452 million yuan, with a total financing and securities balance of 409 million yuan [1] - The financing balance of Nocera Biopharma is 408 million yuan, accounting for 7.66% of its market capitalization, which is above the 90th percentile of the past year, indicating a high level of leverage [1] Group 2 - Nocera Biopharma, established on November 3, 2015, focuses on the research, production, and commercialization of biopharmaceuticals, particularly in oncology and autoimmune diseases [2] - The company's revenue composition includes 87.67% from drug sales, 12.04% from technology licensing, and minimal contributions from testing and research services [2] - For the period from January to September 2025, Nocera Biopharma reported a revenue of 1.115 billion yuan, a year-on-year increase of 59.85%, while the net profit attributable to shareholders was -64.415 million yuan, reflecting a 76.61% year-on-year increase in losses [2] Group 3 - As of September 30, 2025, the top ten circulating shareholders of Nocera Biopharma include several new entrants, such as Wan Jia You Xuan and Ping An Medical Health, while some existing shareholders have reduced their holdings [3] - The sixth-largest shareholder, Fuguo Precision Medical Flexible Allocation Mixed A, decreased its holdings by 427,100 shares, while new shareholders have entered the top ten list [3]

Core Viewpoint - Nanhua Biomedical Co., Ltd. has officially terminated its major asset restructuring plan after nearly six months of planning due to a lack of consensus among the parties involved in the transaction [1][7]. Group 1: Company Background and Performance - The company, formerly known as Hong Kong and Macau Industry, was listed in 1992 and has undergone multiple ownership changes and name changes, finally being renamed "Nanhua Biomedical" in 2015 to enter the biomedical field [4]. - The company has two main businesses: "biomedical" (stem cell and immune cell storage) and "energy conservation and environmental protection," but its performance has been inconsistent, with revenue heavily reliant on cell storage [4]. - The company has oscillated between being under special treatment (ST) and being delisted due to continuous losses, with the most recent instance of being under ST occurring in 2019 [4][5]. Group 2: Termination of Restructuring - The planned acquisition of a 51% stake in Hunan Huize Biomedical Technology Co., Ltd. was intended to expand the biomedical sector but was ultimately terminated due to failure to reach an agreement on the transaction plan [6][7]. - The termination of the restructuring will not have a significant adverse impact on the company's production, operations, or financial status, as it was still in the planning stage and had not entered formal implementation [7][8]. Group 3: Financial Performance and Future Outlook - The company has projected a significant increase in revenue for 2025, estimating between 385 million to 425 million yuan, compared to approximately 130 million yuan in the previous year [10]. - The net profit attributable to shareholders is expected to be between 28.5 million to 32.5 million yuan, marking a turnaround from a loss of 19.846 million yuan in the previous year [11]. - The improvement in financial performance is primarily attributed to the acquisition of Loudi Jinhong New Materials Co., Ltd., which has enhanced revenue from resource recycling businesses [13][14]. - The company is also expanding its product offerings related to its biomedical and environmental protection businesses, contributing to revenue and profit growth [15][16].

Core Insights - The strategic emerging industries are experiencing high growth across various regions in China, with some areas seeing total asset scales exceeding one trillion yuan, supported by increased credit investments from banking institutions [1] Group 1: Credit Investment in Strategic Emerging Industries - Fujian Automotive Industry Group received a one billion yuan strategic emerging loan from China CITIC Bank in just five working days, highlighting the bank's commitment to supporting innovation in the automotive sector [2] - As of November 2025, China CITIC Bank's technology finance loan balance reached 42.79 billion yuan, serving over 9,000 technology enterprises [2] - Agricultural Bank of China reported a 116.85% increase in strategic emerging industry loans, amounting to a growth of 32.6 billion yuan by September 2025, significantly outpacing the average loan growth rate [4] Group 2: Growth in Strategic Emerging Industries - The strategic emerging industries accounted for over 25% of the industrial added value in Henan Province, with significant contributions from advanced equipment, electronic information, and new energy vehicles [5] - Gansu Province's strategic emerging industries achieved revenue of 108.29 billion yuan in 2025, marking a 38.8% year-on-year growth and surpassing the one hundred billion yuan milestone for the first time [6] - Hebei Province's strategic emerging industries saw an 11.0% increase in added value, outpacing the overall industrial growth rate by 3.1 percentage points [7] Group 3: Bank Strategies and Industry Focus - Major banks are focusing on key sectors such as new generation information technology, biomedicine, and high-end equipment to support the development of strategic emerging industries [3] - The growth rate of loans in the strategic emerging industries is reported to be over 20%, significantly exceeding the average growth rate of bank credit [8]

文 | 产业观察室，作者 | 方建华 放眼全球资本市场，纳斯达克指数在苹果、英伟达等硬科技巨头的强力引擎下，演绎了长达二十年的跨周期"慢牛"。 A股传统权重股则集中于金融、能源等领域，上证指数整体呈现"牛短熊长"的走势。 当前，中美在科技、金融及地缘领域的系统性博弈与竞合，正深刻影响全球资本流向与格局重塑。 数据来源：Wind 但与此同时，中国资本市场自2024年9月24以来，持续推进结构性变革。资本市场功能转型、经济新旧动能转换与跨周期资金配置形成同频共振，为股市长 期向好与创投行业崛起筑牢根基。 着眼未来，二级市场有望开启由"科技牛"引领的A股"长牛"新周期，这并非短期脉冲式行情，而是跨越十年以上时间周期的趋势性变革。 科技创新具有无限的延展性与迭代空间，谁也无法定义二级市场新一轮成长逻辑的触顶边界。此时任何臆测这一轮股市的顶点——是5000点抑或6000点？这 都未必准确。 个人以为，在长周期的视角下，8000点乃至10000点或许不是梦想。具体可从以下三个维度进行解构： 其一，中国资本市场加速功能转换，A股"投资性价比"底层逻辑升级。 当下中国资本市场步入"融资+投资"功能转换的关键时期，"融资端提质 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 上海君实生物医药科技股份有限公司（以下简称"公司"）2024年年度股东大会审议通过了《关于发行境 内外债务融资工具的一般性授权的议案》，同意公司注册发行不超过人民币25亿元或等值外币的境内外 债务融资工具，并一般及无条件授权董事会并由董事会转授权董事长及其授权人士根据公司不时的需要 以及市场条件全权决定及办理债务融资工具发行的全部事宜，以及由董事会进一步授权董事长及其授权 人士根据公司需要以及其它市场条件等具体执行债务融资工具发行事宜，详见公司在2025年6月21日于 上海证券交易所网站（www.sse.com.cn）披露的《上海君实生物医药科技股份有限公司2024年年度股东 大会决议公告》（公告编号：临2025-035）。 公司本期科技创新债券发行相关文件详见中国货币网（www.chinamoney.com.cn）、上海清算所网站 （www.shclearing.com）和北京金融资产交易所网站（www.cfae.cn）等交易商协会认可的网站。 特此公告。 上海君实生物医药 ...

Core Insights - The A-share biopharmaceutical companies are expected to deliver innovative results in 2025, benefiting from improving industry conditions, ongoing expansion in overseas markets, and favorable pharmaceutical policies [1] Group 1: Industry Performance - As of January 26, over 90 A-share biopharmaceutical companies have released their 2025 performance forecasts, with 53 companies expecting to achieve profitability [1] - Among the profit forecasts, 14 companies anticipate a doubling of net profits (excluding those recovering from losses) [1] Group 2: Company Highlights - Companies such as Yiling Pharmaceutical and Chutian Technology are among 10 firms expected to turn losses into profits [1] - Other companies like Dize Pharmaceutical and Mengke Pharmaceutical are projected to reduce their losses year-on-year [1] Group 3: Market Signals - The formation of a MACD golden cross signal indicates a positive trend for these stocks [1]

Company Overview - Sanofi Guojian (688336) announced its 2025 annual performance forecast, expecting revenue of approximately 4.2 billion yuan, a year-on-year increase of 251.76%, and a net profit attributable to shareholders of around 2.9 billion yuan, reflecting a growth of 311.35% compared to the previous year [2] - The significant increase in performance is attributed to a major collaboration with Pfizer, which involved a licensing fee payment of approximately 2.89 billion yuan for the 707 project, leading to substantial growth in revenue and net profit [2] Business Development Transactions - In May 2025, Sanofi Guojian, along with its subsidiaries, granted Pfizer exclusive rights for the development, production, and commercialization of the 707 project, a bispecific antibody product targeting PD-1 and VEGF [5] - According to the agreement, Pfizer will pay a non-refundable upfront fee of $1.25 billion, with potential milestone payments reaching up to $4.8 billion, and royalties based on annual net sales in the licensed region [5] Industry Trends - The record-breaking upfront payment of $1.25 billion signifies a reassessment of the value of domestic innovative drugs by international giants and sets a new benchmark for future business development collaborations in the industry [7] - In 2025, China approved 76 innovative drugs, surpassing the previous year's 48, marking a historical high. The total value of innovative drug licensing transactions exceeded $130 billion, with over 150 deals, significantly higher than the previous year's $51.9 billion and 94 deals [7] - The bispecific antibody targeting PD-1/VEGF is emerging as a cornerstone for next-generation cancer therapies, with several domestic companies engaging in business development transactions in this area [7]

Core Viewpoint - Yunnan Province is prioritizing the construction of a modern industrial system through the "14th Five-Year Plan," focusing on key industries and investment to establish itself as a strong industrial province [1][2]. Group 1: Key Industry Development Directions - The industrial blueprint emphasizes three categories: "4+5+6," where "4" includes strengthening resource-based industries such as green aluminum, silicon photovoltaic, phosphorus chemical, and non-ferrous and rare metals [1]. - "5" focuses on consolidating and enhancing five characteristic advantageous industries: plateau characteristic agriculture, cultural tourism, green energy, tobacco, and modern logistics [1]. - "6" targets six key breakthrough areas: biomedicine, new materials, advanced equipment manufacturing, digital economy, low-altitude economy, and biomanufacturing, aiming to develop strategic emerging industries and future industries [1]. Group 2: Implementation and Strategic Focus - The plan requires local governments and departments to understand and implement the strategy effectively, as these selected industries contribute over 90% of the province's industrial added value [2]. - The focus on resource-based industries like aluminum and silicon is based on solid foundations, with an emphasis on extending and strengthening supply chains and improving quality [2]. - The strategy aims to convert resource advantages into industrial strengths, with a focus on major projects that drive significant industrial breakthroughs, particularly in the non-ferrous and rare metals sectors [3].